Myo Htut, MD, Oncology, Duarte, CA, City of Hope's Helford Clinical Research Hospital

MyoHtutMD

Oncology Duarte, CA

Hematologic Oncology

Physician

Dr. Htut is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Htut's full profile

Already have an account?

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Hematology/Oncology, 2007 - 2009
  • Harbor Hospital CenterResidency, Internal Medicine, 1999 - 2002
  • University Institute of Medicine 1
    University Institute of Medicine 1Class of 1996

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2007 - 2011
  • PA State Medical License
    PA State Medical License 2004 - 2006
  • CA State Medical License
    CA State Medical License 2002 - 2023
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Myo Htut, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: Final Analysis of a Phase 1 Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • CD84: A Potential Novel Therapeutic Target in Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative Neoplasm
    OncLive® Presents State of the Science Summit™: Diagnosis, Management, and Treatment of Multiple Myeloma, and Myeloproliferative NeoplasmApril 11th, 2018
  • Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at Upcoming ASH Meeting
    Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at Upcoming ASH MeetingDecember 2nd, 2016

Hospital Affiliations